Dept of Pathology, Magee-Womens Hospital, University of Pittsburgh Medical Center, PA 15213, USA.
Am J Clin Pathol. 2011 Sep;136(3):428-35. doi: 10.1309/AJCPUFNMEZ3MK1BK.
The distinction between breast and müllerian carcinomas from each other and from tumors with a similar cytokeratin profile can be difficult. We tested the usefulness of 2 new markers, NY-BR-1 and PAX8, by staining a variety of breast and gynecologic carcinomas, along with tumors of pancreas, bile ducts, stomach, and gastroesophageal junction. NY-BR-1 expression (ie, H score >10) was seen in 58.4% of breast carcinomas (111/190), 5.6% of müllerian carcinomas (8/142), 7% of pancreatic tumors (1/15), 0% of cholangiocarcinomas (0/22), 0% of gastric tumors (0/36), and 0% of gastroesophageal carcinomas (0/25). All 188 breast carcinomas were negative for PAX8. PAX8 expression was seen in 72.4% of müllerian tumors (105/145). All pancreatic tumors (n = 15), cholangiocarcinomas (n = 23), and gastric (n = 35) and gastroesophageal junction (n = 25) carcinomas were negative for PAX8. Addition of NY-BR-1 and PAX8 in a panel would be useful in distinguishing breast cancer, gynecologic tumors, and tumors of the upper gastrointestinal tract.
鉴别乳腺和苗勒管来源的癌与具有相似细胞角蛋白模式的肿瘤可能具有一定难度。我们通过对各种乳腺和妇科肿瘤，以及胰腺、胆管、胃和胃食管结合部肿瘤进行染色，检测了 2 种新标志物 NY-BR-1 和 PAX8 的实用性。NY-BR-1 表达（即 H 评分>10）见于 58.4%的乳腺肿瘤（111/190）、5.6%的苗勒管肿瘤（8/142）、7%的胰腺肿瘤（1/15）、0%的胆管肿瘤（0/22）、0%的胃肿瘤（0/36）和 0%的胃食管交界部肿瘤（0/25）。所有 188 例乳腺肿瘤均为 PAX8 阴性。PAX8 表达见于 72.4%的苗勒管肿瘤（105/145）。所有胰腺肿瘤（n=15）、胆管肿瘤（n=23）、胃肿瘤（n=35）和胃食管交界部肿瘤（n=25）均为 PAX8 阴性。在一个检测面板中加入 NY-BR-1 和 PAX8 将有助于鉴别乳腺肿瘤、妇科肿瘤和上消化道肿瘤。
